Chemours Company (CC) Stock Forecast, Price Target & Predictions
CC Stock Forecast
Chemours Company stock forecast is as follows: an average price target of $31.44 (represents a 75.15% upside from CC’s last price of $17.95) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
CC Price Target
The average price target for Chemours Company (CC) is $31.44 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $42.00 to $18.00. This represents a potential 75.15% upside from CC's last price of $17.95.
CC Analyst Ratings
According to 14 Wall Street analysts, Chemours Company's rating consensus is 'Buy'. The analyst rating breakdown for CC stock is 0 'Strong Buy' (0.00%), 10 'Buy' (71.43%), 3 'Hold' (21.43%), 0 'Sell' (0.00%), and 1 'Strong Sell' (7.14%).
Chemours Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | John McNulty | BMO Capital | $30.00 | $18.77 | 59.83% | 67.13% |
| Jun 07, 2024 | John Roberts | Mizuho Securities | $25.00 | $23.90 | 4.60% | 39.28% |
| May 29, 2024 | Rich Hilliker | UBS | $31.00 | $26.65 | 16.32% | 72.70% |
| Apr 09, 2024 | John McNulty | BMO Capital | $34.00 | $27.05 | 25.69% | 89.42% |
| Apr 01, 2024 | Joshua Spector | UBS | $28.00 | $28.74 | -2.57% | 55.99% |
| Apr 01, 2024 | Emily Nassedd Mitsch | CFRA | $18.00 | $28.74 | -37.37% | 0.28% |
| Mar 13, 2024 | Linda Bolton Weiser | D.A. Davidson | $24.00 | $26.84 | -10.58% | 33.70% |
| Dec 01, 2023 | Arun Viswanathan | RBC Capital | $40.00 | $29.53 | 35.46% | 122.84% |
| Oct 30, 2023 | Vincent Andrews | Morgan Stanley | $33.00 | $23.58 | 39.95% | 83.84% |
| Jan 10, 2023 | Arun Viswanathan | RBC Capital | $33.00 | $32.55 | 1.38% | 83.84% |
The latest Chemours Company stock forecast, released on Aug 06, 2024 by John McNulty from BMO Capital, set a price target of $30.00, which represents a 59.83% increase from the stock price at the time of the forecast ($18.77), and a 67.13% increase from CC last price ($17.95).
Chemours Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 9 |
| Avg Price Target | - | $30.00 | $29.22 |
| Last Closing Price | $17.95 | $17.95 | $17.95 |
| Upside/Downside | -100.00% | 67.13% | 62.79% |
In the current month, the average price target of Chemours Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Chemours Company's last price of $17.95. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 28, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 28, 2024 | Wells Fargo | Equal-Weight | Underweight | Downgrade |
| Aug 06, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 01, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| May 29, 2024 | UBS | Buy | Buy | Hold |
| Apr 16, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Apr 01, 2024 | UBS | Neutral | Neutral | Hold |
| Apr 01, 2024 | CFRA | Strong Sell | Strong Sell | Hold |
| Jan 18, 2024 | Jefferies | Hold | Hold | Hold |
Chemours Company's last stock rating was published by Wells Fargo on Sep 11, 2024. The company gave CC a "Overweight" rating, the same as its previous rate.
Chemours Company Financial Forecast
Chemours Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.36B | $1.49B | $1.64B | $1.54B | $1.34B | $1.78B | - |
| Avg Forecast | $1.61B | $1.70B | $1.73B | $1.57B | $1.47B | $1.60B | $1.64B | $1.47B | $1.36B | $1.46B | $1.53B | $1.35B | $1.32B | $1.51B | $1.68B | $1.46B | $1.27B | $1.67B | $1.84B |
| High Forecast | $1.64B | $1.73B | $1.76B | $1.60B | $1.50B | $1.62B | $1.67B | $1.49B | $1.38B | $1.48B | $1.55B | $1.37B | $1.34B | $1.54B | $1.71B | $1.49B | $1.29B | $1.70B | $1.84B |
| Low Forecast | $1.58B | $1.68B | $1.71B | $1.55B | $1.45B | $1.57B | $1.61B | $1.45B | $1.34B | $1.43B | $1.51B | $1.33B | $1.30B | $1.49B | $1.65B | $1.44B | $1.25B | $1.65B | $1.84B |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.98% | 0.98% | 1.05% | 1.06% | 1.06% | - |
Chemours Company's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.35B, with a low forecast of $1.33B, and a high forecast of $1.37B. CC's average Quarter revenue forecast represents a -0.85% decrease compared to the company's last Quarter revenue of $1.36B (Dec 23).
Chemours Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-558.00M | $88.00M | $-397.00M | $310.00M | $90.00M | $403.00M | - |
| Avg Forecast | $211.61M | $224.02M | $228.04M | $206.93M | $193.90M | $210.04M | $215.74M | $193.29M | $178.79M | $192.44M | $201.21M | $249.73M | $173.10M | $199.01M | $221.12M | $227.03M | $166.60M | $280.06M | $241.60M |
| High Forecast | $215.08M | $227.68M | $231.77M | $210.31M | $197.07M | $213.48M | $219.27M | $196.45M | $181.72M | $195.14M | $204.50M | $299.67M | $175.63M | $202.27M | $224.74M | $272.43M | $169.32M | $336.07M | $241.60M |
| Low Forecast | $208.21M | $220.42M | $224.37M | $203.60M | $190.78M | $206.66M | $212.28M | $190.19M | $175.92M | $188.41M | $197.98M | $199.78M | $170.58M | $195.81M | $217.57M | $181.62M | $163.92M | $224.04M | $241.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -3.22% | 0.44% | -1.80% | 1.37% | 0.54% | 1.44% | - |
4 analysts predict CC's average Quarter EBITDA for Dec 23 to be $173.10M, with a high of $175.63M and a low of $170.58M. This is 96.71% upper than Chemours Company's previous annual EBITDA (Sep 23) of $88.00M.
Chemours Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-27.00M | $20.00M | $-376.00M | $145.00M | $-97.00M | $240.00M | - |
| Avg Forecast | $117.10M | $145.62M | $169.64M | $117.10M | $93.48M | $120.83M | $129.08M | $85.54M | $43.43M | $44.78M | $85.78M | $147.94M | $40.39M | $103.31M | $162.02M | $134.49M | $14.43M | $168.82M | $211.44M |
| High Forecast | $119.59M | $148.71M | $173.25M | $119.59M | $95.47M | $123.40M | $131.83M | $87.36M | $44.35M | $51.56M | $87.60M | $177.53M | $59.89M | $105.50M | $165.46M | $161.39M | $14.73M | $202.59M | $211.44M |
| Low Forecast | $114.65M | $142.58M | $166.09M | $114.65M | $91.53M | $118.31M | $126.39M | $83.75M | $42.52M | $37.99M | $83.99M | $118.35M | $20.89M | $101.15M | $158.63M | $107.59M | $14.13M | $135.06M | $211.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.67% | 0.19% | -2.32% | 1.08% | -6.72% | 1.42% | - |
Chemours Company's average Quarter net income forecast for Dec 23 is $40.39M, with a range of $20.89M to $59.89M. CC's average Quarter net income forecast represents a 101.94% increase compared to the company's last Quarter net income of $20.00M (Sep 23).
Chemours Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $222.00M | $165.00M | $779.00M | $124.00M | $175.00M | $140.00M | - |
| Avg Forecast | $198.54M | $210.18M | $213.95M | $194.15M | $181.92M | $197.07M | $202.42M | $181.35M | $167.75M | $180.56M | $188.78M | $89.14M | $162.41M | $186.72M | $207.46M | $81.04M | $156.31M | $97.82M | $226.68M |
| High Forecast | $201.79M | $213.62M | $217.45M | $197.32M | $184.90M | $200.29M | $205.73M | $184.32M | $170.49M | $183.08M | $191.87M | $106.97M | $164.78M | $189.77M | $210.86M | $97.25M | $158.87M | $117.39M | $226.68M |
| Low Forecast | $195.35M | $206.81M | $210.52M | $191.03M | $179.00M | $193.90M | $199.17M | $178.44M | $165.05M | $176.77M | $185.75M | $71.31M | $160.04M | $183.72M | $204.13M | $64.83M | $153.80M | $78.26M | $226.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.37% | 0.88% | 3.75% | 1.53% | 1.12% | 1.43% | - |
Chemours Company's average Quarter SG&A projection for Mar 24 is $89.14M, based on 2 Wall Street analysts, with a range of $71.31M to $106.97M. The forecast indicates a -59.85% fall compared to CC last annual SG&A of $222.00M (Dec 23).
Chemours Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.18 | $0.13 | $-2.52 | $0.97 | $-0.59 | $1.54 | - |
| Avg Forecast | $0.78 | $0.97 | $1.13 | $0.78 | $0.62 | $0.80 | $0.86 | $0.57 | $0.29 | $0.30 | $0.57 | $0.18 | $0.27 | $0.69 | $1.08 | $0.46 | $0.10 | $1.04 | $1.41 |
| High Forecast | $0.80 | $0.99 | $1.15 | $0.80 | $0.64 | $0.82 | $0.88 | $0.58 | $0.30 | $0.34 | $0.58 | $0.19 | $0.40 | $0.70 | $1.10 | $0.47 | $0.10 | $1.07 | $1.41 |
| Low Forecast | $0.76 | $0.95 | $1.11 | $0.76 | $0.61 | $0.79 | $0.84 | $0.56 | $0.28 | $0.25 | $0.56 | $0.18 | $0.14 | $0.67 | $1.06 | $0.45 | $0.09 | $1.02 | $1.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.67% | 0.19% | -2.33% | 2.11% | -6.14% | 1.48% | - |
According to 4 Wall Street analysts, Chemours Company's projected average Quarter EPS for Dec 23 is $0.27, with a low estimate of $0.14 and a high estimate of $0.40. This represents a 106.95% increase compared to CC previous annual EPS of $0.13 (Sep 23).
Chemours Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OEC | Orion Engineered Carbons | $16.91 | $32.00 | 89.24% | Buy |
| CC | Chemours Company | $17.95 | $31.44 | 75.15% | Buy |
| ECVT | Ecovyst | $6.68 | $10.00 | 49.70% | Buy |
| WTTR | Select Energy Services | $10.64 | $14.50 | 36.28% | Buy |
| ASH | Ashland | $86.70 | $117.30 | 35.29% | Buy |
| PPG | PPG Industries | $126.98 | $162.41 | 27.90% | Buy |
| KWR | Quaker Chemical | $164.69 | $197.50 | 19.92% | Buy |
| WLK | Westlake | $138.93 | $158.64 | 14.19% | Hold |
| SXT | Sensient | $75.53 | $85.00 | 12.54% | - |
| LYB | LyondellBasell Industries | $93.18 | $102.47 | 9.97% | Buy |
| FUL | H.B. Fuller Company | $80.78 | $85.60 | 5.97% | Buy |
| APD | Air Products and Chemicals | $284.13 | $300.08 | 5.61% | Hold |
| AXTA | Axalta Coating Systems | $34.80 | $36.73 | 5.55% | Buy |
| IFF | International Flavors & Fragrances | $103.59 | $108.23 | 4.48% | Buy |
| ESI | Element Solutions | $25.62 | $25.60 | -0.08% | Buy |
| CBT | Cabot | $104.75 | $99.50 | -5.01% | Hold |
| LIN | Linde | $468.81 | $424.58 | -9.43% | Buy |
| PRM | Perimeter Solutions, SA | $11.97 | $7.00 | -41.52% | Hold |
CC Forecast FAQ
Is Chemours Company a good buy?
Yes, according to 14 Wall Street analysts, Chemours Company (CC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 71.43% of CC's total ratings.
What is CC's price target?
Chemours Company (CC) average price target is $31.44 with a range of $18 to $42, implying a 75.15% from its last price of $17.95. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Chemours Company stock go up soon?
According to Wall Street analysts' prediction for CC stock, the company can go up by 75.15% (from the last price of $17.95 to the average price target of $31.44), up by 133.98% based on the highest stock price target, and up by 0.28% based on the lowest stock price target.
Can Chemours Company stock reach $30?
CC's average twelve months analyst stock price target of $31.44 supports the claim that Chemours Company can reach $30 in the near future.
What are Chemours Company's analysts' financial forecasts?
Chemours Company's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.18B (high $6.28B, low $6.08B), average EBITDA is $812.97M (high $826.27M, low $799.91M), average net income is $428.93M (high $438.05M, low $419.98M), average SG&A $762.76M (high $775.24M, low $750.5M), and average EPS is $2.86 (high $2.92, low $2.8). CC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.62B (high $6.73B, low $6.51B), average EBITDA is $870.6M (high $884.84M, low $856.61M), average net income is $549.45M (high $561.13M, low $537.97M), average SG&A $816.83M (high $830.19M, low $803.7M), and average EPS is $3.66 (high $3.74, low $3.58).
Did the CC's actual financial results beat the analysts' financial forecasts?
Based on Chemours Company's last annual report (Dec 2023), the company's revenue was $6.03B, beating the average analysts forecast of $5.97B by 0.87%. Apple's EBITDA was $-92M, missing the average prediction of $820.26M by -111.22%. The company's net income was $-238M, missing the average estimation of $440.2M by -154.07%. Apple's SG&A was $1.29B, beating the average forecast of $637.63M by 102.31%. Lastly, the company's EPS was $-1.6, missing the average prediction of $2.5 by -164.12%. In terms of the last quarterly report (Dec 2023), Chemours Company's revenue was $1.36B, beating the average analysts' forecast of $1.32B by 3.42%. The company's EBITDA was $-558M, missing the average prediction of $173.1M by -422.35%. Chemours Company's net income was $-27M, missing the average estimation of $40.39M by -166.85%. The company's SG&A was $222M, beating the average forecast of $162.41M by 36.69%. Lastly, the company's EPS was $-0.18, missing the average prediction of $0.269 by -166.91%